Enanta Q1 revenue $18M, net loss $33.4M; RSV data expected Q3 2024

ENANTA PHARMACEUTICALS INC

2024-Q1 EPS reported -$1.58 revenue$18,003,000

Revenue $18.0M (down from $23.6M YoY) from AbbVie's MAVYRET royalties; net loss $33.4M ($1.58/share) vs $29.0M loss YoY.
Cash and marketable securities $337.2M; expected to fund operations through fiscal 2027.
Anticipates topline data from RSVPEDs Phase 2 study of zelicapavir and EDP-323 Phase 2a challenge study in Q3 2024.
Expanded into immunology with oral KIT inhibitor program for chronic spontaneous urticaria; development candidate selection targeted for 2024.
G&A expenses rose to $16.5M due to legal fees from patent infringement suit against Pfizer and higher stock compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.